Smithfield Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Smithfield Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-205	Closed	-$11K	–	1089
2025 Q3	$11K	Hold	205	–	–	﹤0.01%	838
2025 Q2	$11K	Hold	205	–	–	﹤0.01%	839
2025 Q1	$14K	Hold	205	–	–	﹤0.01%	798
2024 Q4	$13K	Hold	205	–	–	﹤0.01%	822
2024 Q3	$14K	Hold	205	–	–	﹤0.01%	780
2024 Q2	$17K	Hold	205	–	–	﹤0.01%	730
2024 Q1	$18K	Hold	205	–	–	﹤0.01%	740
2023 Q4	$20K	Hold	205	–	–	﹤0.01%	705
2023 Q3	$18K	Hold	205	–	–	﹤0.01%	693
2023 Q2	$18K	Hold	205	–	–	﹤0.01%	709
2023 Q1	$20K	Hold	205	–	–	﹤0.01%	657
2022 Q4	$21K	Hold	205	–	–	﹤0.01%	635
2022 Q3	$17K	Hold	205	–	–	﹤0.01%	664
2022 Q2	$17K	Hold	205	–	–	﹤0.01%	697
2022 Q1	$16K	Hold	205	–	–	﹤0.01%	738
2021 Q4	$18K	Hold	205	–	–	﹤0.01%	729
2021 Q3	$16K	Hold	205	–	–	﹤0.01%	743
2021 Q2	$17K	Hold	205	–	–	﹤0.01%	722
2021 Q1	$15K	Hold	205	–	–	﹤0.01%	753
2020 Q4	$18K	Hold	205	–	–	﹤0.01%	691
2020 Q3	$16K	Hold	205	–	–	﹤0.01%	666
2020 Q2	$25K	Buy	+205	New	+$20.4K	﹤0.01%	588
2019 Q4	–	Sell	-14	Closed	-$1K	–	952
2019 Q3	$1K	Hold	14	–	–	﹤0.01%	973
2019 Q2	$1K	Hold	14	–	–	﹤0.01%	957
2019 Q1	$1K	Buy	+14	New	+$1.3K	﹤0.01%	923
2018 Q3	–	Sell	-60	Closed	-$6K	–	1001
2018 Q2	$6K	Buy	+60	New	+$5.25K	﹤0.01%	792

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Smithfield Trust's BMRN Position: Q4 2025 in Review

Smithfield Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 205 shares — an estimated $11K sold.

Smithfield Trust first reported a position in BMRN in Q2 2018 and held it in 26 quarters. The position peaked at $25K in Q2 2020. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Smithfield Trust reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Smithfield Trust sold 205 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $11K.
Smithfield Trust first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 26 quarters.
Smithfield Trust's BioMarin Pharmaceuticals position peaked at $25K in Q2 2020.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Smithfield Trust's 13F filing for Q4 2025, filed 9 Feb 2026.